Обзорная статья

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

Nicola AmodioMagna Graecia University and T. Campanella Cancer Center, Department of Experimental and Clinical Medicine, Medical Oncology Unit, Viale Europa, 88100 Catanzaro, ItalyMaria Teresa Di MartinoMagna Graecia University and T. Campanella Cancer Center, Department of Experimental and Clinical Medicine, Medical Oncology Unit, Viale Europa, 88100 Catanzaro, Italy +39 0961 3697029; +39 0961 3697341; [email protected]Antonino NeriUniversity of Milan, Department of Clinical Sciences and Community Health, Hematology 1, IRCCS Policlinico Foundation, Milan, ItalyPierosandro TagliaferriMagna Graecia University and T. Campanella Cancer Center, Department of Experimental and Clinical Medicine, Medical Oncology Unit, Viale Europa, 88100 Catanzaro, Italy +39 0961 3697029; +39 0961 3697341; [email protected]Pierfrancesco TassoneMagna Graecia University and T. Campanella Cancer Center, Department of Experimental and Clinical Medicine, Medical Oncology Unit, Viale Europa, 88100 Catanzaro, Italy +39 0961 3697029; +39 0961 3697341; [email protected]; Temple University, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Philadelphia, PA, USA

2013en

ABI

Аннотация

INTRODUCTION: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. AREAS COVERED: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. EXPERT OPINION: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.

Перевод пока недоступен

Идентификаторы

DOI: 10.1517/14712598.2013.796356

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar